1. Home
  2. PLUS vs TRVI Comparison

PLUS vs TRVI Comparison

Compare PLUS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ePlus inc.

PLUS

ePlus inc.

N/A

Current Price

$95.07

Market Cap

2.3B

Sector

Technology

ML Signal

N/A

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

N/A

Current Price

$14.67

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLUS
TRVI
Founded
1990
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.9B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
PLUS
TRVI
Price
$95.07
$14.67
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $28.18
AVG Volume (30 Days)
219.8K
★ 1.8M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 1.14%
N/A
EPS Growth
24.20
★ 31.91
EPS
★ 2.72
N/A
Revenue
★ $2,442,549,000.00
N/A
Revenue This Year
$4.67
N/A
Revenue Next Year
$4.89
N/A
P/E Ratio
$34.71
★ N/A
Revenue Growth
★ 18.07
N/A
52 Week Low
$73.09
$9.82
52 Week High
$98.21
$20.22

Technical Indicators

Market Signals
Indicator
PLUS
TRVI
Relative Strength Index (RSI) 54.64 57.32
Support Level $85.87 $13.08
Resistance Level $98.03 $14.75
Average True Range (ATR) 4.31 0.81
MACD -0.13 0.29
Stochastic Oscillator 84.64 74.09

Price Performance

Historical Comparison
PLUS
TRVI

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: